Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27.85 SEK | -0.71% | +0.72% | -46.44% |
03-14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
02-15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 155M 14.1M 1.13B | Sales 2025 * | 238M 21.71M 1.73B | Capitalization | 1.84B 167M 13.36B |
---|---|---|---|---|---|
Net income 2024 * | 37M 3.37M 269M | Net income 2025 * | 37M 3.37M 269M | EV / Sales 2024 * | 11.1 x |
Net cash position 2024 * | 120M 10.92M 872M | Net cash position 2025 * | 93M 8.47M 677M | EV / Sales 2025 * | 7.32 x |
P/E ratio 2024 * |
48.9
x | P/E ratio 2025 * |
21.3
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
1 day | -0.71% | ||
1 week | +0.72% | ||
Current month | -16.62% | ||
1 month | -20.99% | ||
3 months | -44.85% | ||
6 months | -33.21% | ||
Current year | -46.44% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 31/12/01 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 31/12/21 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 04/05/20 | |
Director/Board Member | 63 | 31/12/18 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 31/12/13 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 27.85 | -0.71% | 23 596 |
29/04/24 | 28.05 | -1.58% | 97,499 |
26/04/24 | 28.5 | +9.83% | 168,012 |
25/04/24 | 25.95 | -3.53% | 96,355 |
24/04/24 | 26.9 | -2.71% | 273,179 |
Delayed Quote Nasdaq Stockholm, April 30, 2024 at 11:52 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.44% | 168M | |
+1.09% | 12.95B | |
-7.57% | 7.84B | |
+1.63% | 5.5B | |
+0.93% | 4.61B | |
+7.16% | 4.61B | |
-48.54% | 3.4B | |
+9.21% | 2.66B | |
-14.59% | 2.08B | |
+4.18% | 1.79B |
- Stock Market
- Equities
- GENO Stock